Int J Clin Oncol. 2022 Sep 27. doi: 10.1007/s10147-022-02237-2. Online ahead of print.
NO ABSTRACT
PMID:36166110 | DOI:10.1007/s10147-022-02237-2
Categories
Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19)
